- Trials with a EudraCT protocol (57)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
57 result(s) found for: Immune System Diseases AND Graft Versus Host Disease.
Displaying page 1 of 3.
EudraCT Number: 2015-001550-14 | Sponsor Protocol Number: ECP-GVHD1 | Start Date*: 2015-06-09 | |||||||||||
Sponsor Name:Bispebjerg hospital | |||||||||||||
Full Title: Extracorporeal Photopheresis Treatment in steroid refractory acute and chronic Graft versus Host Disease | |||||||||||||
Medical condition: Acute and chronic Graft versus Host Disease (GVHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004529-57 | Sponsor Protocol Number: EQ-100-02 | Start Date*: 2022-06-24 | ||||||||||||||||
Sponsor Name:Equillium Inc. | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease | ||||||||||||||||||
Medical condition: Acute Graft Versus Host Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) FR (Not Authorised) BE (Ongoing) DE (Ongoing) PT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022780-35 | Sponsor Protocol Number: 10-005 | Start Date*: 2011-07-06 | |||||||||||
Sponsor Name:THERAKOS, Inc. | |||||||||||||
Full Title: A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX™ for the Treatment of Patients with Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD) | |||||||||||||
Medical condition: Chronic graft-versus-host disease (cGvHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) AT (Completed) ES (Completed) IT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004847-35 | Sponsor Protocol Number: PredEver_first | Start Date*: 2012-09-07 | ||||||||||||||||||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | ||||||||||||||||||||||||||||
Full Title: Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first) - A prospective multicenterphase IIA study - | ||||||||||||||||||||||||||||
Medical condition: chronic Graft versus Host Disease | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000894-22 | Sponsor Protocol Number: MAGIC-HR-ECP | Start Date*: 2019-12-10 | |||||||||||
Sponsor Name:Department of Stem Cell Transplantation - University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Phase II multicenter study of extracorporeal photopheresis with UvadexTM plus standard steroid treatment for high risk acute Graft-versus-Host Disease | |||||||||||||
Medical condition: New onset high risk acute GvHD following allogeneic SCT | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018594-37 | Sponsor Protocol Number: EMN-alloRIC2010 | Start Date*: 2013-01-24 | ||||||||||||||||
Sponsor Name:European Myeloma Network | ||||||||||||||||||
Full Title: European Myeloma Network sequential phase I / phase II trial on RIC allogeneic transplantation: an optimized program for high risk relapsed patients | ||||||||||||||||||
Medical condition: Allogeneic transplantation for patients with multiple myeloma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004806-14 | Sponsor Protocol Number: TKS-2014-001 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Therakos, Inc. | |||||||||||||
Full Title: Single-Arm Study to Assess the Efficacy of UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute ... | |||||||||||||
Medical condition: Acute graft-versus-host disease (aGvHD) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) GB (Completed) IT (Completed) ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004267-20 | Sponsor Protocol Number: RIG-P000814 | Start Date*: 2016-09-01 | |||||||||||
Sponsor Name:Medical Center - University of Freiburg | |||||||||||||
Full Title: Multicenter, randomized Phase 2 Trial to determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) versus BAT in Steroid-refractory acute Graft-versus-Host Disease (aGvHD) | |||||||||||||
Medical condition: Steroid-refractory acute Graft-versus-Host Disease (GvHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000329-29 | Sponsor Protocol Number: CSL964_2001 | Start Date*: 2019-05-31 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft-versus-host disease in patients ... | |||||||||||||
Medical condition: Graft versus host disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003237-33 | Sponsor Protocol Number: HO112 | Start Date*: 2013-11-21 | ||||||||||||||||
Sponsor Name:HOVON Foundation | ||||||||||||||||||
Full Title: Treatment of severe GVHD after allogeneic hematopoietic stem cell transplanatation with MSCs and steroid versus steroids alone. A prospective double-blind placebo-controlled randomized phase III t... | ||||||||||||||||||
Medical condition: Graft Versus Host Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000538-78 | Sponsor Protocol Number: INCB39110-301 | Start Date*: 2017-09-14 | ||||||||||||||||||||||||||
Sponsor Name:Incyte Corporation | ||||||||||||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft Versus-Host Disease | ||||||||||||||||||||||||||||
Medical condition: Male or female, 18 years of age or older who have received an allogeneic hematopoietic stem cell transplant (allo-HSCT) and have developed Grade II to IV acute GVHD | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) BE (Completed) AT (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) GR (Completed) FI (Completed) IT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004915-30 | Sponsor Protocol Number: HO113 | Start Date*: 2013-09-05 | ||||||||||||||||
Sponsor Name:HOVON Foundation | ||||||||||||||||||
Full Title: Treatment of severe steroid-refractory acute GvHD with mesenchymal stromal cells. A phase III, randomized double-blind multi-center HOVON study. | ||||||||||||||||||
Medical condition: Graft Versus Host Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) DE (Ongoing) BE (Ongoing) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005009-24 | Sponsor Protocol Number: INO-0107 | Start Date*: 2008-05-15 | |||||||||||
Sponsor Name:EUSA Pharma | |||||||||||||
Full Title: An international randomised, multicentre, parallel-group, Phase III comparative study of inolimomab against usual care in the Treatment of Primary Steroid Refractory Acute Graft versus Host Disease... | |||||||||||||
Medical condition: Steroid refractory acute Graft versus Host Disease (aGvHD) after Allogeneic Haematopoietic Stem Cell Transplantation in adult patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000068-27 | Sponsor Protocol Number: XEN/TG-001 | Start Date*: 2013-11-29 | |||||||||||
Sponsor Name:Xenikos BV | |||||||||||||
Full Title: A Phase Ib/IIa multicentric study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins (T-Guard) for the treatment of steroid-resistant acute Graft-vers... | |||||||||||||
Medical condition: Acute Graft-versus-Host Disease (GVHD) not responding on regular first line therapy of 2 mg/kg corticosteroids daily. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001606-29 | Sponsor Protocol Number: INCB39110-309 | Start Date*: 2019-04-03 | ||||||||||||||||||||||||||
Sponsor Name:Incyte Corporation | ||||||||||||||||||||||||||||
Full Title: GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | ||||||||||||||||||||||||||||
Medical condition: Moderate or severe cGVHD | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing) SE (Completed) DE (Prematurely Ended) PL (Completed) DK (Completed) ES (Temporarily Halted) GR (Prematurely Ended) FI (Completed) IT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005659-19 | Sponsor Protocol Number: RG_14-287 | Start Date*: 2015-10-21 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A phase II study of the use of azacitidine for the treatment of patients with chronic graft-versus-host-disease who have failed therapy with corticosteroids | |||||||||||||
Medical condition: Chronic Graft versus Host Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004588-29 | Sponsor Protocol Number: TA799-101 | Start Date*: 2022-02-01 | ||||||||||||||||||||||||||
Sponsor Name:VectivBio AG | ||||||||||||||||||||||||||||
Full Title: A randomized, single-blind trial to evaluate the safety and efficacy of apraglutide in subjects with Grade II to IV (MAGIC) steroid refractory gastrointestinal (GI) acute graft versus host disease ... | ||||||||||||||||||||||||||||
Medical condition: Acute graft versus host disease (aGVHD) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) PT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002253-30 | Sponsor Protocol Number: INCB39110-120 | Start Date*: 2019-07-01 | ||||||||||||||||||||||||||
Sponsor Name:Incyte Corporation | ||||||||||||||||||||||||||||
Full Title: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in... | ||||||||||||||||||||||||||||
Medical condition: Male or female, 28 days to less than 18 years of age, who have received an allogeneic hematopoietic stem cell transplant (allo-HSCT) and have developed Grade II to IV acute GVHD | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-004562-10 | Sponsor Protocol Number: BUM-5/GVH | Start Date*: 2009-07-29 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomised, placebo-controlled multicentre phase III clinical study followed by open-label phase on the efficacy and tolerability of budesonide 3 mg effervescent tablet in patients wi... | |||||||||||||
Medical condition: Oral chronic graft versus host disease as a complication of haematopoietic stem cell transplantation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Completed) FR (Completed) SE (Completed) IT (Completed) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004558-41 | Sponsor Protocol Number: PCYC-1146-IM | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Pharmacyclics LLC | |||||||||||||
Full Title: Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD) | |||||||||||||
Medical condition: Chronic Graft Versus Host Disease (cGVHD) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) NL (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.